Sanofi

SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors

Retrieved on: 
Monday, October 17, 2022
SAN, Proteomics, Therapy, Growth, UCB, NASDAQ, Roche, Foundation Medicine, SomaLogic, Nasdaq, Senior, Acquisition, Schering-Plough, Board, CEO, Health, Chair, GLOBE, Sanofi, Leadership, Management, Genentech

BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the companys Board of Directors.

Key Points: 
  • BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the companys Board of Directors.
  • Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board.
  • Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche, valuing Foundation Medicine at $5.3 billion.
  • We are very pleased to appoint Mr. Cox as Executive Chair of SomaLogics Board of Directors, said SomaLogic Chief Executive Officer Roy Smythe, M.D.

Ochre Bio Announces Formation of Scientific Strategy Board with Liver Disease Experts

Retrieved on: 
Thursday, October 20, 2022
Technology, Research, Genetics, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Institute of Liver and Biliary Sciences, Bio, Koch Institute, PRO, Therapy, Liver disease, Koch Institute for Integrative Cancer Research, Science, University of Oxford, Strategic planning, Takeda, Patient, IMES, Biology, RNA, Tissue, Translational medicine, Division, Multimedia, Institute, Sanofi, GI, Technology, SVP, Extramural medical education in Edinburgh, Ragon Institute, Broad Institute, Industry, Obesity, Eric Schmidt, MIT, Faculty, Innovation, Associate, Ochre, CMO, Cirrhosis, Greater, Death, Chronic liver disease, SSB, Management, Pharmaceutical industry, Dietary supplement, Chemistry, Engineering, Novartis

Ochre Bio , an RNA therapeutics company focused on chronic liver and cardiometabolic diseases, announced today the formation of its scientific strategy board (SSB) to support the maturation of its platforms and pipeline of liver disease therapeutics.

Key Points: 
  • Ochre Bio , an RNA therapeutics company focused on chronic liver and cardiometabolic diseases, announced today the formation of its scientific strategy board (SSB) to support the maturation of its platforms and pipeline of liver disease therapeutics.
  • The SSB comprises leading experts across liver disease R&D, clinical development, and pharmaceutical partnering.
  • The company is developing a novel strategy that has potential to positively impact all patients with liver diseases.
  • Ochre is basically de-risking clinical trials, so more of the trials in liver disease will hopefully be successful.

Slone Partners Places Patrick Genestin as Chief Business Officer at 1910 Genetics

Retrieved on: 
Thursday, October 20, 2022
People, Genetics, Hikma Pharmaceuticals, Doctor of Philosophy, Neuroscience, Biotechnology, Immunology, MBA, Artificial intelligence, Precision medicine, Technology, Automation, Infection, Ajman Specialty General Hospital, Pennsylvania State University, Probability, Drug discovery, AI, Business development, Specialty, CSL Behring, Lead, Engineering, Pharmaceutical industry, Management, Sanofi, Novartis

SOUTH RIDING, Va., Oct. 20, 2022 /PRNewswire-PRWeb/ --- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Patrick Genestin as Chief Business Officer at 1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation, and biological automation to accelerate the design of small molecule and protein therapeutics.

Key Points: 
  • Before joining 1910 Genetics, Genestin served as Vice President of Business Development and Pipeline Strategy at Hikma Pharmaceuticals and a member of the Specialty & Generics leadership team.
  • "Patrick Genestin is an extremely accomplished, passionate, and respected business leader with a penchant for establishing strategic partnerships, attracting new investment, and stimulating growth," said Slone Partners CEO Leslie Loveless .
  • "He brings solid experience across financial, portfolio, and business development operations and is well prepared to help advance 1910 Genetics through key collaborations & partnerships."
  • "Patrick's extensive experience working with industry leaders and creating value-added deals for companies makes him an invaluable addition to the 1910 Genetics executive team," said Jen Nwankwo, Ph.D. , 1910 Genetics' Founder and Chief Executive Officer.

Aqemia Raises €30M to Scale its Deep Physics and AI Enabled Drug Discovery Pipeline

Retrieved on: 
Wednesday, October 19, 2022
Research, Technology, Other Technology, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Launch pad, New Senior Investment Group, Machine learning, COO, Patient, Euronext Paris, Research, Investment, Sanofi, Technology, École normale supérieure (Paris), VC, Drug discovery, AI, CEO, Series, Physics, Artificial intelligence, Janssen, DNA, SME, CNRS, Algorithm, Yunnan Normal University, Pharmaceutical industry, Medical device, Financial services, Security (finance), Chemistry, Greentech, Eurazeo, Bpifrance, Elaia, Association of British HealthTech Industries

This financing will further support Aqemias core mission: to massively scale drug discovery, through a first-in-class technological platform combining quantum-inspired physics and machine learning.

Key Points: 
  • This financing will further support Aqemias core mission: to massively scale drug discovery, through a first-in-class technological platform combining quantum-inspired physics and machine learning.
  • The unprecedented pace a whopping 10,000x faster while maintaining costs - and accuracy of our deep physics algorithms, adding up to our generative AI, creates a unique combination that permits to generate innovative new drug candidates more quickly, and scale drug discovery projects as technology projects.
  • Aqemia's ambition is to optimize and accelerate early drug discovery projects on a massive scale in order to uncover dozens of proprietary new drug candidates.
  • The disruptive speed and accuracy of our technology platform allows us to scale drug discovery projects as technology projects.

NIIMBL and BioPhorum Announce the Full Release of the Full Data and Design Models for the New Buffer Stock Blending System for Open Access

Retrieved on: 
Tuesday, October 18, 2022
Adoption, National Institute, U.S. Department of Defense Strategy for Operating in Cyberspace, Merck, GSK, U.S. Department of Commerce Office of Security, Commerce, NIST, Merck Millipore, CGMP, Biogen, Sanofi, Partnership, Phorum, Manufacturing USA, Industry, Buffer, Pharmacy, Thermo Fisher Scientific, Environment, Data analysis, Solution, Rockwell Automation, Fine chemical, Technology, Takeda

These solutions constitute the largest proportion by volume of a bioprocessing run and contribute to significant costs in facility footprint, labor, and capital.

Key Points: 
  • These solutions constitute the largest proportion by volume of a bioprocessing run and contribute to significant costs in facility footprint, labor, and capital.
  • BioPhorum was delighted to partner with NIIMBL, which funded and led the fabrication and testing in its facility."
  • The NIIMBL BioPhorum Buffer Stock Blending System prototype model is currently located at the NIIMBL headquarters in Newark, Delaware.
  • To learn more about NIIMBL and the NIIMBL BioPhorum Buffer Stock Blending System visit NIIMBL.org and to access more information about the design of the buffer visit BioPhorum .

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

Retrieved on: 
Thursday, October 13, 2022
LinkedIn, U.S. Securities and Exchange Commission, Therapy, Risk, HS, IND, Science, AML, MAD, MDM2, Degenerative disease, Annual report, NASDAQ, Neoplasm, Patient, Biotechnology, Twitter, Security (finance), STAT3, Immunomodulatory imide drug, Boston Business Journal, Sanofi, Nasdaq, Precision medicine, Private Securities Litigation Reform Act, Boston, Single, PBMC, Lymphatic system, DLBCL, Atopic dermatitis, Adult, Safety, SAD, Food, AD, Skin, Lymphoma, GLOBE, Plasma, Apoptosis, COVID-19, Cancer, Pharmaceutical industry, Medicine, Medical imaging, Part, IRAK4, Black Majesty

WATERTOWN, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will hold an investor webcast on December 14 to present clinical data from the KT-474 Phase 1 HS and AD patient cohort (Part C) and its oncology pipeline.

Key Points: 
  • Kymera recently completed dosing in Part C of the Phase 1 clinical trial evaluating its IRAK4 degrader KT-474.
  • Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immune-oncology fields.
  • KT-333 is a potent and selective heterobifunctional small molecule protein degrader of the STAT3 protein in development for oncology indications.
  • Kymera will hold a webcast for investors on December 14 from 8:00 a.m. to 9:30 a.m. to share clinical data from the KT-474 Phase I patient cohort and oncology pipeline.

IO Biotech Announces Appointment of New Chief Financial Officer

Retrieved on: 
Thursday, October 13, 2022
Euronext, Securities Act of 1933, Sale, Medicine, Science, Biotechnology, Drug development, IO, Genencor, Bentley University, AMAG Pharmaceuticals, Nasdaq, Fortune 500, Cancer, Monmouthshire, Salem State University, Securities Exchange Act of 1934, BV, GLOBE, Forward-looking statement, IDO, FDA, PD-L1, Management, Sanofi

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, today announced the appointment of Amy Sullivan as the companys new Chief Financial Officer.

Key Points: 
  • NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, today announced the appointment of Amy Sullivan as the companys new Chief Financial Officer.
  • We are pleased to welcome Amy to the executive team, said Mai-Britt Zocca, Ph.D., President and Chief Executive Officer of IO Biotech.
  • Her financial prowess and successful track record guiding biotechnology companies through significant organizational growth will be an invaluable addition to IO Biotech.
  • Ms. Sullivan joins IO Biotech from TABA, BV, where she served as chief financial officer.

Early Launch Metrics Reveal an Impressive Start for Sanofi/Regeneron's Dupixent in Eosinophilic Esophagitis, According to Recent Research Conducted by Spherix Global Insights

Retrieved on: 
Friday, October 14, 2022
Adoption, Allergist, Physician, Eosinophilic esophagitis, Patient, Research, Sanofi, Degenerative disease, Budesonide, Gastroenterology, Benchmarking, Nephrology, Regeneron Pharmaceuticals, Pharmaceutical industry, Generic drug, Dupilumab, EOE

EXTON, Pa., Oct. 14, 2022 /PRNewswire/ -- In May of 2022, Sanofi/Regeneron's Dupixent (dupilumab) was granted approval by the U.S. FDA to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older, making the IL-4/13 inhibitor the first approved treatment for this debilitating disease. Spherix Global Insights' recent research via their Launch Dynamix™: Dupixent in EoE (US) service reveals swift uptake and unprecedented projected use of the brand at just three months post-approval. Indeed, nearly half of physicians (n=64 gastroenterologists and 10 allergists), sampled in September, report that they have already initiated trial of the drug in at least one EoE patient. 

Key Points: 
  • Spherix Global Insights' recent research via their Launch Dynamix: Dupixent in EoE (US) service reveals swift uptake and unprecedented projected use of the brand at just three months post-approval.
  • The vast majority of those reporting early experience also state that they are overall very satisfied with Dupixent.
  • Help, in any way, get the patient on the medication, whether it's financial, whether it's benefits verification, whatever it is."
  • Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence.

19th Annual Eurocom Worldwide Conference in Barcelona Showcased Best Global Coverage Ever

Retrieved on: 
Thursday, October 13, 2022
People, Trust, Uncertainty, Communication, Study of global communication, Conference, Social, CUPRA, Organization, Data communication, PR, New Formations, Sanofi, History, Technology, Generation, EMG, Industry, CEO, Taieb, SEAT, Generation Z, Robin, Commerce, Rubus chamaemorus, Leadership, Airline, Public relations, Liberian Bank for Development and Investment, Eurocom, PepsiCo

BARCELONA, Spain, Oct. 13, 2022 /PRNewswire-PRWeb/ -- The 19th Eurocom Worldwide Annual Conference held on Sept. 30, 2022, in Barcelona demonstrated the power of Eurocom's global PR network. The three-day conference included 30 agency leaders from around the world and combined social networking events with a meeting agenda that covered crucial communication industry and cultural transformation trends.

Key Points: 
  • BARCELONA, Spain, Oct. 13, 2022 /PRNewswire-PRWeb/ -- The 19th Eurocom Worldwide Annual Conference held on Sept. 30, 2022, in Barcelona demonstrated the power of Eurocom's global PR network.
  • "Our annual conference in Barcelona impressed with the growing strength of the Eurocom Worldwide network.
  • Despite the global pandemic and the war in Ukraine, Eurocom Worldwide has achieved its strongest global coverage ever in 2022 with 29 member agencies covering 80 countries in Europe, the U.S. and Latin America, Asia Pacific and the Middle East.
  • Eurocom Worldwide was established in 2002 and is today one of the leading global networks of independent, privately-owned PR and marketing communications agencies.

1910 Genetics Appoints Patrick Genestin as Chief Business Officer

Retrieved on: 
Tuesday, October 11, 2022
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Research, Software, Artificial Intelligence, Genetics, Science, Genetics, Hikma Pharmaceuticals, Disease, Therapy, Neuroscience, Patient, Immunology, Multimedia, Artificial intelligence, Partnership, Technology, Infection, Ajman Specialty General Hospital, Pennsylvania State University, Probability, Drug discovery, AI, Business development, Specialty, CSL Behring, Lead, Engineering, Pharmaceutical industry, Management, Sanofi, Novartis

1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to accelerate the design of small molecule and protein therapeutics, today announced that it has appointed Patrick Genestin as Chief Business Officer.

Key Points: 
  • 1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation and biological automation to accelerate the design of small molecule and protein therapeutics, today announced that it has appointed Patrick Genestin as Chief Business Officer.
  • Patricks extensive experience working with industry leaders and creating value-added deals for companies makes him an invaluable addition to the 1910 Genetics executive team, said Jen Nwankwo, Ph.D., 1910 Genetics Founder and Chief Executive Officer.
  • Prior to joining 1910 Genetics, Genestin served as Vice President of Business Development and Pipeline Strategy at Hikma Pharmaceuticals and member of the Specialty & Generics leadership team.
  • I am excited to join 1910 Genetics at such a pivotal time for the company, Genestin said.